Nutex Health (NUTX) 10-K 31 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-53862
Entity Registrant Name	CLINIGENCE HOLDINGS, INC.
Entity Central Index Key	0001479681
Entity Tax Identification Number	11-3363609
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2455 East Sunrise Blvd.
Entity Address, Address Line Two	Suite 1204
Entity Address, City or Town	Fort Lauderdale
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33304
City Area Code	(954)
Local Phone Number	449-4703
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	CLNH
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 86,250,000
Entity Common Stock, Shares Outstanding		48,444,979
Auditor Firm ID	688
Auditor Name	Marcum LLP
Auditor Location	New York, NY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 15,314,328	$ 26,931
Accounts receivable	647,325	18,283
Accounts receivable – ACMG sale of investment	1,333,130
Stock subscriptions receivable	100,000	0
Prepaid expenses and other current assets	301,275	111,842
Total current assets	17,696,058	157,056
Long-term assets
Property and equipment, net	14,935	12,391
Right of use asset, net	98,008	0
Intangible assets, net	10,585,592	0
Goodwill	57,338,935	0
Deposits and other assets	0	410
Total assets	85,733,528	169,857
Current liabilities
Accounts payable and accrued expenses	3,505,197	695,424
Customer deposits	1,960	38,651
Accrued interest on notes payable	154,502	0
Due to related parties	128,176	30,000
Lease liability - current	46,593	0
Deferred revenue	173,919	76,687
Convertible notes payable, net of debt discount	3,904,221	0
Current portion of notes payable	727,182	312,890
Total current liabilities	8,641,750	1,153,652
Long-term liabilities
Lease liability - long term	55,906	0
Deferred tax liabilities	1,747,250
Notes payable	150,000	150,000
Total liabilities	10,594,906	1,303,652
Stockholders' equity (deficiency)
Preferred stock, $.001 par value; authorized - 100,000,000 shares; issued and outstanding - 0 shares in 2021 and 2020, respectively	0	0
Common stock, $.001 par value; authorized - 800,000,000 shares; 48,232,076 and 5,282,545 shares issued and outstanding as of December 31, 2021 and 2020, respectively	48,232	5,282
Additional paid-in capital	106,977,976	17,079,885
Accumulated deficit	(31,888,477)	(18,218,962)
Noncontrolling interest	891	0
Total stockholders' equity (deficiency)	75,138,622	(1,133,795)
Total liabilities and stockholders' equity (deficiency)	$ 85,733,528	$ 169,857

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares issued	48,232,076	5,282,545
Common stock, shares outstanding	48,232,076	5,282,545

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Sales
Capitation revenue, net	$ 16,620,488	$ 0
SaaS revenue	1,653,806	1,585,952
Management service revenue, net	519,489	0
Total sales	18,793,783	1,585,952
Cost of sales	14,647,045	909,780
Gross profit	4,146,738	676,172
Operating expenses
Research and development	285,880	557,257
Sales and marketing	24,449	166,759
General and administrative expenses	12,177,316	3,251,353
Goodwill impairment loss	0	3,471,508
Gain on sale of assets	0	(8,395,702)
Gain on lease termination	0	(25,174)
Loss on sale of fixed assets	0	54,819
Amortization	677,168	222,032
Total operating expenses	13,164,813	(697,148)
Income (loss) from operations	(9,018,075)	1,373,320
Other income (expenses)
Loss on extinguishment of debt	0	(167,797)
Settlement payment from ACMG	522,000	0
Income from forgiveness of debt	636,807	0
Impairment of Series E investment	0	(6,402,278)
Interest income	917	1,030
Interest expense – debt obligation	(784,012)	0
Interest expense – accretion of debt discount	(6,011,071)	(335,450)
Total other income (expenses)	(5,635,359)	(6,904,495)
Loss from continuing operations	(14,653,434)	(5,531,175)
Income tax benefit – deferred	984,810	0
Loss from discontinued operations (including gain on disposal of $142,027 for the year ended December 31, 2020)	0	(118,992)
Net loss	(13,668,624)	(5,650,167)
Net income attributable to noncontrolling interest	891	0
Net income (loss) attributable to Clinigence Holdings, Inc.	$ (13,669,515)	$ (5,650,167)
Basic and fully diluted income (loss) per common share:
Continuing operations	$ (0.37)	$ (1.12)
Discontinued operations	0	(0.02)
Net income (loss) per common share	$ (0.37)	$ (1.14)
Weighted average common shares outstanding - basic and fully diluted	37,325,057	4,942,268

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)	12 Months Ended
	Dec. 31, 2020USD ($)
Income Statement [Abstract]
Gain on disposal	$ 142,027

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDER'S EQUITY (DEFICIENCY) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 4,649	$ 14,422,579	$ (12,568,795)		$ 1,858,433
Beginning balance, Shares at Dec. 31, 2019	4,649,179
Common stock issued for cash	$ 190	119,810			120,000
Common stock issued for cash, Shares	190,476
Stock-based compensation	$ 466	2,571,223			2,571,689
Stock-based compensation shares	466,166
Common stock cancelled	$ (23)	(33,727)			(33,750)
Common stock cancelled shares	(23,276)
Net loss			(5,650,167)		(5,650,167)
Ending balance, value at Dec. 31, 2020	$ 5,282	17,079,885	(18,218,962)		(1,133,795)
End balance, Shares at Dec. 31, 2020	5,282,545
Common stock issued for cash	$ 7,471	14,315,968			14,323,439
Common stock issued for cash, Shares	7,470,894
Common stock subscribed	$ 57	99,943			100,000
Common stock subscribed shares	57,142
Financing cost for capital raise		(1,013,500)			(1,013,500)
Common stock issued for related party note payable	$ 46	29,954			30,000
Common stock issued for related party note, Shares	46,154
Common stock issued in business acquisitions	$ 33,793	70,892,153			70,925,946
Common stock issued in business acquisitions, shares	33,793,503
Notes payable converted to common stock	$ 1,366	2,393,634			2,395,000
Notes payable converted to common stock, Shares	1,365,501
Warrants converted to common stock	$ 107	153,317			153,424
Warrants converted to common stock shares	106,578
Options converted to common stock	$ 89	178,753			178,842
Options converted to common stock, shares	89,421
Stock-based compensation	$ 933	4,025,951			4,026,884
Stock-based compensation shares	932,567
Return of common stock held back in AHP acquisition	$ (1,076)	(2,216,250)			(2,217,326)
Return of common stock held back in AHP acquisition shares	(1,076,372)
Debt discount on notes payable		659,755			659,755
Adjustment to common stock issued in AHA acquisition	$ 184	378,393			378,577
Adjustment to common stock issued in AHA acquisition shares	183,775
Prior period adjustment to common stock	$ (20)	20
Prior period adjustment to common stock, shares	(19,632)
Net loss			(13,669,515)	891	(13,668,624)
Ending balance, value at Dec. 31, 2021	$ 48,232	$ 106,977,976	$ (31,888,477)	$ 891	$ 75,138,622
End balance, Shares at Dec. 31, 2021	48,232,076

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (13,668,624)	$ (5,650,167)
(Income) loss from discontinued operations	0	118,992
Net loss from continuing operations	(13,668,624)	(5,531,175)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	4,648	14,514
Amortization	709,131	94,761
Interest expense associated with debt discount	6,011,071	0
Non cash interest expense	24,372	474,344
Purchase price adjustment to investment in AHP	(300,000)	0
Settlement payment from ACMG	(522,000)	0
Income from forgiveness of debt	(633,125)	0
Deferred income tax benefit	(984,810)	0
Stock-based compensation expense	4,026,884	2,571,689
Goodwill impairment loss	0	3,471,508
Gain on sale of assets	0	(8,395,702)
Impairment of investment	0	6,402,278
Gain on lease termination	0	(25,174)
Loss on sale of assets	0	54,819
Cancellation of common stock	0	(33,750)
Loss on extinguishment of debt	0	167,797
Changes in operating assets and liabilities:
Accounts receivable	(74,880)	71,900
Prepaid expenses and other current assets	(161,155)	(65,467)
Deposits and other assets	410	10,411
Accounts payable and accrued expenses	(1,365,554)	(648,475)
Customer deposits	(36,691)	38,651
Accrued interest on notes payable	197,033	(21,730)
Lease liability	(27,472)	(37,401)
Deferred revenue	97,232	(88,873)
NET CASH USED IN OPERATING ACTIVITIES	(6,703,530)	(1,475,075)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of investment in ACMG	4,554,676	0
Distribution from investment in ACMG	522,000	0
Advances to acquisition target
(Increase) decrease in restricted cash	0	100,000
Sale of property and equipment	0	500
Payment to AHP shareholder for litigation settlement	(1,094,689)	0
Preacquisition loans from subsidiary	85,000	0
Cash acquired from acquisitions	3,884,583	0
Net cash provided by in continuing investing activities	7,951,570	100,500
Net cash used in discontinued investing activities	0	(161,400)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	7,951,570	(60,900)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	14,323,439	120,000
Proceeds from exercise of warrants	153,424	0
Proceeds from exercise of options	178,842	0
Proceeds from issuance of notes and convertible notes payable	413,917	461,125
Payments on notes payable	(16,765)
Payments of financing costs for capital raise	(1,013,500)	0
Proceeds from related party loans	0	30,000
Payments on notes and convertible notes payable	0	(113,653)
NET CASH PROVIDED BY FINANCING ACTIVITIES	14,039,357	497,472
NET INCREASE (DECREASE) IN CASH	15,287,397	(1,038,503)
CASH - BEGINNING OF YEAR	26,931	1,065,434
CASH - END OF YEAR	15,314,328	26,931
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest	651,838	18,077
Non-cash investing and financing activities:
Sale of software in consideration of Series E preferred stock, convertible notes and other liabilities assumed	0	3,470,385
Common stock issued for acquisition of subsidiaries	69,087,197	0
Common stock issued for subscriptions receivable	100,000
Purchase price adjustment to investment in AHA	1,246,194	0
Related party loans converted to common stock	30,000	0
Notes payable converted to accounts payable	228,518	0
Notes payable converted to common stock	2,395,000	0
Accrued interest converted to convertible notes payable	54,746	0
Deferred tax liability recorded on intangible assets	2,868,560	0
Debt discount on notes payable	659,755	0
Right of use asset added for operating lease	$ 129,971	$ 0

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Organization and Basis of Presentation	Note 1 - Organization and Basis of Presentation The consolidated financial statements presented are those of Clinigence Holdings, Inc., formerly known as iGambit Inc., (the “Company”) and its wholly-owned subsidiaries, Accountable Healthcare America, Inc. (“AHA”), AHP Management, Inc. (“AHP”), Clinigence Health, Inc. (“Clinigence”), Procare Health, Inc. (“Procare”) and HealthDatix, Inc. (“HealthDatix”). The Company’s name was changed to Clinigence Holdings, Inc. on October 29, 2019 in connection with a reverse merger. In October 2018, Clinigence was incorporated as a wholly-owned subsidiary of Clinigence LLC. The Company is a population health analytics company that provides turnkey SaaS solutions that enable connected intelligence across the care continuum by transforming massive amounts of data into actionable insights. The Company’s solutions help healthcare organizations throughout the United States improve the quality and cost-effectiveness of care, enhance population health management and optimize provider networks. The Company enables risk-bearing healthcare organizations achieve their objectives on the path to value-based care. The Company’s platform automatically extracts and delivers targeted data insights from its cloud-based analytics engine directly to the workflows and technologies of its customers. This enhances end-user workflows with actionable analytics, seamlessly delivers data from disparate sources to the point of engagement, automates the delivery of data to ensure on-time access, and reduces dependency on non-essential applications from the end-user’s workflow. All of this allows the healthcare organization to enable population health management, manage cost and utilization, improve quality, identify gaps in care, risk stratify and target patients, increase collaboration among providers and to optimize network provider performance. AHA was organized to acquire a series of companies providing a broad array of health and managed care services to Medicare members. AHA’s initial focus is on acquiring Accountable Care Organizations (“ACO’s”), Managed Service Organizations (“MSO’s”) and Primary Care Physician Practices (“PCP’s”) with significant numbers of Medicare members. AHP is a privately held medical management company and provider network that manages its affiliated medical group, AHP Independent Physicians Association. ProCare is a leading management services organization (“MSO”) that currently provides services for one health maintenance organization (“HMO”) and three independent physician associations (“IPAs”) in Southern and Northern California. Business Acquisitions Merger With Procare Health, Inc. On October 15, 2021, Clinigence Holdings, Inc., a Delaware corporation (“Parent” or the “Company”), Clinigence Procare Health Inc, a Delaware corporation (“Merger Sub”), Procare Health, Inc., a California corporation (“Procare”), Anh Nguyen (“Majority Stockholder”), and Tram Nguyen (“Minority Stockholder” and together with Majority Stockholder, the “Stockholders”) entered into an agreement and plan of merger (the “Merger Agreement”). The transactions contemplated by the Merger Agreement were consummated on October 15, 2021 (the “Procare Closing”). The Merger Agreement provided for the merger of Merger Sub with and into Procare, h ereafter referred to as the “Procare Acquisition.” Merger With AHP Health Management Services Inc. On February 25, 2021, Clinigence Holdings, Inc., a Delaware corporation (“Parent” or the “Company”), AHP, Inc., a California corporation (“AHP”), AHP Acquisition Corp., a Delaware corporation, a wholly owned subsidiary of Parent (“Merger Sub”), and Robert Chan (the “Shareholders’ Representative”) entered into an agreement and plan of merger (the “AHP Merger Agreement”). The transactions contemplated by the AHP Merger Agreement were consummated on February 26, 2021 (the “AHP Closing”). The AHP Merger Agreement provided for the merger of Merger Sub with and into AHP, h ereafter referred to as the “AHP Acquisition.” AHP was a privately held company with controlling interest in its’ affiliate Associated Hispanic Physicians of Southern California IPA, a California Medical corporation, (“AHPIPA”). A key term of the AHP Merger Agreement is that at Closing, AHP Management Inc entered into a Management Services Agreement with AHPIPA (the “Management Services Agreements”) making AHPIPA a Variable Interest Entity (VIE) of Clinigence. Merger With Accountable Healthcare America, Inc. On February 25, 2021, Clinigence Holdings, Inc., a Delaware corporation (“Parent” or the “Company”), Accountable Healthcare America, Inc., a Delaware corporation (“AHA”), and AHA Acquisition Corp., a Delaware corporation, a wholly owned subsidiary of Parent (“Merger Sub”) entered into an agreement and plan of merger (the “AHA Merger Agreement”). The transactions contemplated by the AHA Merger Agreement were consummated on February 26, 2021 (the “AHA Closing”). The AHA Merger Agreement provided for the merger of Merger Sub with and into AHA, h ereafter referred to as the “AHA Acquisition.” Pursuant to the Procare Merger Agreement, at the Closing, the former Procare Stockholders were entitled to receive an aggregate of 759,036 Company Shares, 607,229 shares of which were valued at $4.00 per share with the remaining 151,807 shares valued at $446,018, are being held back and will be released subject to Procare achieving certain earnings milestones. Pursuant to the AHP Merger Agreement, at the Closing, the former AHP Stockholders were entitled to receive 19,000,000 Company Shares valued at $2.06 per share, inclusive of outstanding AHP options and warrants assumed by the Company, which constitutes 45% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options and warrants. For each share of AHP Shares, each former AHP Stockholder was entitled to receive 19,000,000 shares of Company Shares valued at $2.06 per share. Pursuant to the AHA Merger Agreement, at the Closing, the former AHA Stockholders were entitled to receive 14,034,472 Company Shares, inclusive of certain outstanding AHA options and warrants assumed by the Company, which constitutes 35% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options and warrants The following table presents the preliminary allocation of the value of the common shares issued for Procare to the acquired identifiable assets, liabilities assumed and goodwill: Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Fair Value Cash $ 81,316 Accounts receivable 284,847 Property and equipment 7,192 Management contracts 1,864,530 Trademarks 226,230 Accounts payable (95,236 ) Deferred tax liability - intangibles (439,060 ) Goodwill 945,115 Purchase price $ 2,874,934 The following table presents the allocation of the value of the common shares issued for AHA to the acquired identifiable assets, liabilities assumed and goodwill: Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Fair Value Cash $ 697,191 Other current assets 2,100 Investment in ACMG 7,134,000 PHP technology 2,183,000 Loan to Clinigence 85,000 Accounts payable (1,143,106 ) Due to related party (128,176 ) Notes payable (1,784,155 ) Deferred tax liability - intangibles (545,750 ) Goodwill 22,789,787 Purchase price $ 29,289,591 On December 24, 2021, the AHA Investment in ACMG was sold for $ 5,887,806 4,554,676 1,333,130 1,246,194 The following table presents the allocation of the value of the common shares issued for AHP to the acquired identifiable assets, liabilities assumed and goodwill: Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Fair Value Cash $ 3,105,877 Accounts receivable 269,315 Deposits and other assets 26,178 Member relationships 6,444,000 Trademarks 545,000 Accounts payable (2,683,896 ) Distribution payable (300,000 ) Deferred tax liability - intangibles (1,747,250 ) Goodwill 33,480,776 Purchase price $ 39,140,000 On September 30, 2021, the Company paid out an arbitration settlement on behalf of AHP. Pursuant to the merger agreement with AHP this triggered the release of 1,076,372 common shares that were subject to a holdback provision pending the outcome of the arbitration case (the “AHP Litigation Holdback Shares”) back to the Company. As a result of the release of the AHP Litigation Holdback shares to Clinigence Holdings, Inc. goodwill was decreased by $ 1,122,636 The results of operations of AHA and AHP for the period March 1, 2021 to December 31, 2021 have been included in the consolidated statements of operations for the year ended December 31, 2021. The following table presents unaudited pro forma results of operations of the Company and AHA and AHP as if the acquisitions had occurred at January 1, 2020. The pro forma condensed financial information is presented for informational purposes only. The unaudited pro forma results of operations are not necessarily indicative of results that would have occurred had the acquisition taken place at the beginning of the earliest period presented, or of future results. Pro forma results of operation December 31, December 31, 2021 2020 Pro forma revenue $ 21,934,587 $ 20,776,209 Pro forma gross profit $ 4,647,452 $ 4,182,625 Pro forma loss from operations $ (15,215,466 ) $ (8,296,319 ) Pro forma net loss $ (12,346,906 ) $ (6,368,689 ) Pro forma net income (loss) per share $ (0.33 ) $ (1.29 ) Weighted average number of shares outstanding 37,325,057 4,942,268 Liquidity and Management Plans The Company has an accumulated deficit of $ 31,888,477 6 Historically, the Company’s major sources of cash have been comprised of proceeds from various public and private offerings of its common stock, debt financings, and option and warrant exercises. During the year ended December 31, 2021, the Company raised approximately $14.4 million in gross proceeds from various public and private offerings of its common stock. As of December 31, 2021, the Company had approximately $ 15.3 The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2021
Discontinued Operations
Discontinued Operations	Note 2 – Discontinued Operations Sale of Business On April 21, 2020 (effective March 1, 2020) the Company completed the sale of HealthDatix, Inc., a Florida corporation (“HDX FL”) to Jerry Robinson, Mary-Jo Robinson and Kathleen Shepherd (“HDX Management”) in accordance with a Stock Purchase Agreement (the “Purchase Agreement”) by and between the Company and HDX Management. Pursuant to the Purchase Agreement, the total consideration paid for the outstanding capital stock of HDX FL was the execution of Settlement and Release Agreements by HDX Management, releasing the Company from all obligations pursuant to certain HDX Management Employment Agreements dated April 1, 2017, and remittance of 1,000 shares of HDX common stock previously issued to HDX Management. As per the Purchase Agreement, the Company’s operations of HDX FL ended February 29, 2020 and HDX Management’s operation of the business is effective as of March 1, 2020. The components of loss from discontinued operations presented in the consolidated statements of operations for the year ended December 31, 2020 are presented as follows: Schedule of consolidated statements of operations Sales $ 5,958 Cost of sales (6,795 ) General and administrative expenses (101,100 ) Depreciation and amortization (75 ) Interest expense (263 ) Loss from operations (102,275 ) Loss on disposal of HealthDatix (16,717 ) Loss from discontinued operations $ (118,992 )

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Clinigence Health, Inc., Accountable Healthcare America Inc., AHP Management Inc., and Procare Health, Inc. All intercompany accounts and transactions have been eliminated. Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company’s significant estimates used in these financial statements include, but are not limited to, accounts receivable reserves, the valuation allowance related to the Company’s deferred tax assets, the recoverability and useful lives of long-lived assets, debt conversion features, stock-based compensation, certain assumptions related to the valuation of the reserved shares and the assets acquired and liabilities assumed related to the Company’s acquisitions. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Variable Interest Entities On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly-owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company’s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria: •The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and •The Company has a variable interest in the legal entity – i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity’s net assets. If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs. A legal entity is determined to be a VIE if it has any of the following three characteristics: 1. The entity does not have sufficient equity to finance its activities without additional subordinated financial support; 2. The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or 3. The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following: a. The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity’s economic performance, as evidenced by: i. Substantive participating rights in day-to-day management of the entity’s activities; or ii. Substantive kick-out rights over the party responsible for significant decisions; iii. The obligation to absorb the entity’s expected losses; or iv. The right to receive the entity’s expected residual returns. If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model. Variable interest model If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 17 – “Variable Interest Entities (VIEs)” to the consolidated financial statements for information on the Company’s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting. Cash and Cash Equivalents Cash and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does not have any cash equivalents as of December 31, 2021 and 2020. The Company is exposed to credit risk in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. Accounts Receivable The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment. As of December 31, 2021, no customers represented more than 10% of total accounts receivable. Property and equipment and depreciation Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows: Schedule of estimated lives of respective assets Office equipment and fixtures 5 7 Computer hardware 5 Computer software 3 Development equipment 5 Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows: Schedule of estimated lives of the respective assets Population Health Platform technology 11 Member relationships 15 Management contracts 15 years 15 Trademarks 6 10 Goodwill Goodwill represents the net identifiable assets acquired and the liabilities assumed of Procare, AHA and AHP and the fair market value of the common shares issued by the Company for the acquisition of Procare, AHA and AHP. In accordance with ASC Topic No. 350 “Intangibles – Goodwill and Other”), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be sufficient to recover the asset’s carrying amount, an impairment loss is charged to expense in the period identified. No impairment was recorded during the year ended December 31, 2021. Long-Lived Assets The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows. Deferred Revenue Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $ 173,919 76,687 Stock-Based Compensation The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements . Fair Value Measurements The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. The Company’s investment in AHA was valued at level 3 input. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities. Revenue Recognition Revenue is generated by software licenses, training, and consulting. Software licenses are provided as SaaS-based subscriptions that grants access to proprietary online databases and data management solutions. Training and consulting are project based and billable to customers on a monthly-basis or task-basis. Revenue from training and consulting are generally recognized upon delivery of training or completion of the consulting project. The duration of training and consulting projects are typically a few weeks or months and last no longer than 12 months. SaaS-based subscriptions are generally marketed under multi-year agreements with annual, semi-annual, quarterly, or month-to-month renewals and revenue is recognized ratably over the renewal period with the unearned amounts received recorded as deferred revenue. For multiple-element arrangements accounted for in accordance with specific software accounting guidance, multiple deliverables are segregated into units of accounting which are delivered items that have value to a customer on a standalone basis. On January 1, 2019, the Company adopted the new revenue recognition standard Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit. Revenue from substantially all the Company’s contracts with customers continues to be recognized over time as performance obligations are satisfied. The Company provides its customers with software licensing, training, and consulting through SaaS-based subscriptions. This subscription revenue represents revenue earned under contracts in which the Company bills and collects the charges for licensing and related services. The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles: 1. Identifying the contract with a customer; 2. Identifying the performance obligations in the contract; 3. Determining the transaction price; 4. Allocating the transaction price to the performance obligations in the contract; and 5. Recognizing revenue when (or as) the Company satisfies its performance obligations. Revenues from subscriptions are deferred and recorded as deferred revenue when cash payments are received in advance of the satisfaction of the Company’s performance obligations and recognized over the period in which the performance obligations are satisfied. The Company completes its contractual performance obligations through providing its customers access to specified data through subscriptions for a service period, and training on consulting associated with the subscriptions. The Company primarily invoices its customers on a monthly basis and does not provide any refunds, rights of return, or warranties to its customers. AHA’s performance obligation is to manage ACO participants who provide healthcare services to CMS’s members for the purpose of generating shared savings. If achieved, the Company receives shared savings payments from CMS, which represents variable consideration. The shared savings payments are recognized using the most likely methodology. However, as the Company does not have sufficient insight from CMS into the financial performance of the shared risk pool because of unknown factors related to shifting patient count, risk adjustment factors and benchmark adjustments, among other factors, an estimate cannot be developed. Therefore, these amounts are considered to be fully constrained and only recorded in the months when such payments are known and/or received. The Company generally receives payment within ten months after the fiscal year-end. AHP negotiates fixed per-member, per-month (PMPM) rates (Capitation) with third-party insurers for a fixed period of time. The Independent Physicians Association (“IPA”) recognizes capitation payments received in advance from third-party insurers as revenue on a monthly basis without regard to the frequency, extent, or nature of the medical services actually furnished. Procare’s revenue is generated primarily through management fees that are received based on Gross Capitation Revenues of the IPA/Physician Groups. Revenue is paid monthly and is a flat fixed rate determined by the agreement. In addition to Management Fees, there is revenue generated through consultant services that are charged as a flat fixed rate and represent a small portion of the total revenue. Advertising Costs The Company expenses advertising costs as incurred. Advertising costs of $ 24,449 41,418 Recent Accounting Pronouncements We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4 – Property and Equipment Property and equipment are carried at cost and consist of the following at December 31, 2021 and 2020: Schedule of property, plant and equipment 2021 2020 Office equipment and fixtures $ 5,300 $ 5,300 Computer hardware 52,998 41,065 Computer software 16,121 16,121 Less: Accumulated depreciation (59,484 ) (50,095 ) Property, Plant and Equipment, Net $ 14,935 $ 12,391 Depreciation expense of $ 4,648 14,514

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 5 – Intangible Assets The following tables provide detail associated with the Company’s acquired identifiable intangible assets: Schedule of intangible assets As of December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted Average Useful Life (in years) Amortized intangible assets: Member relationships $ 6,444,000 $ (358,000 ) $ 6,086,000 15 Management contracts 1,864,530 (31,076 ) 1,833,454 15 Trademarks 771,230 (81,350 ) 689,880 6 10 PHP technology 2,183,000 (206,742 ) 1,976,258 11 Total $ 11,262,760 $ (677,168 $ 10,585,592 Schedule of future amortization expenses Aggregate Amortization Expense: For the year ended December 31, 2021 $ 677,168

Investment in ACMG

Investment in ACMG	12 Months Ended
	Dec. 31, 2021
Investments, All Other Investments [Abstract]
Investment in ACMG	Note 6 – Investment in ACMG In connection with the acquisition of Accountable Care Medical Group of Florida, Inc. (“ACMG”), AHA defaulted on its payment obligations of $ 15,000,000 29 7,134,000 5,887,806 1,333,130 522,000

Operating Lease

Operating Lease	12 Months Ended
	Dec. 31, 2021
Operating Lease
Operating Lease	Note 7 – Operating Lease The Company determines if a contract is, or contains, a lease at contract inception. Operating leases are included in operating lease right-of-use ("ROU") assets, current portion of operating lease liabilities and operating lease liabilities, net of current portion in the Company's consolidated balance sheets. Finance leases are included in property and equipment, current portion of finance lease obligations and finance lease obligations, net of current portion in the Company's audited consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. In addition, ROU assets include initial direct costs incurred by the lessee as well as any lease payments made at or before the commencement date and exclude lease incentives. The Company used the implicit rate in the lease in determining the present value of lease payments. Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of one year or less are generally not included in ROU assets and liabilities. Operating lease ROU assets and operating lease liabilities are recorded on the consolidated balance sheet as follows: Schedule Operating lease ROU assets and operating lease liabilities December 31, 2021 Operating Lease: Operating lease right-of-use assets, net $ 98,008 Current portion of operating lease liabilities 46,593 Operating lease liabilities, net of current portion 55,906 As of December 31, 2021, the weighted-average remaining lease term of the operating lease was 2.1 6.75 The following table summarizes maturities of operating lease liabilities based on lease term as of December 31, 2021: Schedule summarizes maturities of operating lease liabilities 2022 $ 51,800 2023 53,354 2024 4,457 Total lease payments 109,611 Less: Imputed interest 7,112 Present value of lease liabilities $ 102,499 At December 31, 2021, the Company had the following future minimum payments due under the non-cancelable lease: Schedule minimum payments due under the non-cancelable lease 2022 $ 51,800 2023 53,354 2024 4,457 Total minimum lease payments $ 109,611 Consolidated rental expense for all operating leases was $ 100,009 143,307 The following table summarizes the cash paid and related right-of-use operating lease recognized for the year ended December 31, 2021. Schedule of cash paid and related right-of-use operating lease recognized Year Ended December 31, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 50,292 Right-of-use lease assets obtained in the exchange for lease liabilities: Operating leases 27,472 Effective October 15, 2020, the Company terminated the operating lease for its Atlanta, Georgia office that was set to expire in 2024. The lease termination agreement required the Company to forfeit its Letter of Credit and all of its furniture and fixtures to the landlord. The early termination resulted in a gain on lease termination of $ 25,174 Schedule of gain on lease termination Current portion of operating lease liabilities at September 30, 2020 $ 54,564 Operating lease liabilities, net of current portion at September 30, 2020 182,059 Less: Operating lease right-of-use assets, net at September 30, 2020 211,449 Gain on lease termination $ 25,174 The balance of the Letter of Credit of $ 100,000 53,198

Earnings (Loss) Per Common Shar

Earnings (Loss) Per Common Share	12 Months Ended
	Dec. 31, 2021
Basic and fully diluted income (loss) per common share:
Earnings (Loss) Per Common Share	Note 8 - Earnings (Loss) Per Common Share The Company calculates net income (loss) per common share in accordance with ASC 260 “ Earnings Per Share Computation of diluted net income (loss) per share Years Ended December 31, 2021 2020 Stock options 2,876,010 1,174,814 Stock warrants 12,383,550 557,873 Total shares excluded from calculation 15,259,560 1,732,687

Stock Based Compensation

Stock Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock Based Compensation	Note 9 – Stock Based Compensation Options In 2019, the Company adopted the 2019 Omnibus Equity Incentive Plan (the "2019 Plan"). Awards granted under the 2019 Plan have a ten-year term and may be incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units or performance shares. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a four year period. Stock option activity during the years ended December 31, 2021 and 2020 follows: Schedule of stock option activities Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Options outstanding at December 31, 2019 48,854 $ 5.11 8.05 Options granted 1,130,734 1.49 Options expired (400 ) 0.01 Options cancelled (4,374 ) 5.56 Options outstanding at December 31, 2020 1,174,814 1.61 8.11 Options granted 1,300,000 1.66 Options issued in merger 490,617 2.00 Options exercised (89,421 ) 2.00 Options outstanding at December 31, 2021 2,876,010 $ 1.69 6.90 Options outstanding at December 31, 2021 consist of: Schedule of stock options outstanding Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date August 5, 2019 40,480 40,480 $ 5.56 August 5, 2029 October 29, 2019 3,600 3,600 $ 0.0725 June 6, 2027 January 27, 2020 307,884 307,884 $ 1.50 January 27, 2030 January 27, 2020 225,000 225,000 $ 1.50 January 27, 2027 February 29, 2020 95,794 95,794 $ 1.25 February 28, 2030 May 11, 2020 380,000 380,000 $ 1.50 May 11, 2027 June 30, 2020 122,056 122,056 $ 1.45 June 30, 2030 January 28, 2021 1,000,000 1,000,000 $ 1.61 January 28, 2031 January 28, 2021 225,000 225,000 $ 1.61 January 28, 2028 February 25, 2021 201,196 201,196 $ 2.00 March 15, 2025 February 25, 2021 200,000 200,000 $ 2.00 February 25, 2031 August 16, 2021 75,000 75,000 $ 2.51 August 16, 2027 Total 2,876,010 2,876,010 Warrants In 2018, the Company issued fully vested warrants to investors as part of a private placement offering. Each unit offered in the private placement consisted of one share of common stock, and a warrant convertible into 0.4 shares of common stock at an exercise of $1.50 per whole share. The warrants are exercisable for a period of five years from the date of issuance. The warrants were cancelled on March 1, 2019 and reissued upon the Qualmetrix acquisition and are each convertible into one share of common stock at an exercise price of $6.67 per share until December 31, 2024. In November 2019, the Company issued fully vested warrants to investors as part of private placement subscription agreements pursuant to which the Company issued convertible promissory notes. Each noteholder received warrants to purchase common stock of 50% of the principal at an exercise price of $5.56 per share with an expiration date of October 31, 2025. Warrant activity during the years ended December 31, 2021 and 2020 follows: Schedule of Warrants, Activity Warrants Warrants Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Warrants outstanding at December 31, 2019 1,065,251 $ 6.04 5.17 Warrants cancelled (507,378 ) — Warrants outstanding at December 31, 2020 557,873 6.77 3.79 Warrants granted 5,522,748 1.90 Warrants issued in merger 6,415,965 1.74 Warrants exercised (113,036 ) 1.45 Warrants outstanding at December 31, 2021 12,383,550 $ 2.04 4.64 Warrants outstanding at December 31, 2021 consist of: Schedule of Outstanding Warrants Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 21, 2019 96,433 96,433 $ 6.67 December 31, 2024 April 30, 2019 3,598 3,598 $ 6.67 December 31, 2024 May 13, 2019 14,393 14,393 $ 6.67 December 31, 2024 May 28, 2019 199,703 199,703 $ 6.67 December 31, 2024 June 5, 2019 7,197 7,197 $ 6.67 December 31, 2024 June 25, 2019 208,361 208,361 $ 6.67 December 31, 2024 September 6, 2019 25,188 25,188 $ 6.67 December 31, 2024 October 29, 2019 1,500 1,500 $ 25.00 February 5, 2023 October 29, 2019 1,500 1,500 $ 25.00 April 27, 2023 February 25, 2021 1,666,573 1,666,573 $ 1.55 October 31, 2025 February 25, 2021 500,000 500,000 $ 4.00 February 26, 2026 February 25, 2021 1,456,452 1,456,452 $ 1.55 February 1, 2027 February 25, 2021 2,694,190 2,694,190 $ 1.55 July 31, 2026 May 14, 2021 651,429 651,429 $ 1.75 May 30, 2027 May 28, 2021 228,571 228,571 $ 1.75 May 30, 2027 June 11, 2021 182,857 182,857 $ 1.75 May 30, 2027 June 22, 2021 137,143 137,143 $ 1.75 May 30, 2027 June 24, 2021 169,143 169,143 $ 1.75 May 30, 2027 June 28, 2021 45,714 45,714 $ 1.75 May 30, 2027 June 29, 2021 45,714 45,714 $ 1.75 May 30, 2027 July 6, 2021 28,571 28,571 $ 1.75 May 31, 2027 July 22, 2021 12,857 12,857 $ 1.75 May 31, 2027 July 29, 2021 57,142 57,142 $ 1.75 May 31, 2027 August 6, 2021 157,143 157,143 $ 1.75 May 31, 2027 August 10, 2021 14,286 14,286 $ 1.75 May 31, 2027 August 11, 2021 128,143 128,143 $ 1.75 May 31, 2027 August 12, 2021 42,857 42,857 $ 1.75 May 31, 2027 August 16, 2021 14,286 14,286 $ 1.75 May 31, 2027 August 17, 2021 14,286 14,286 $ 1.75 May 31, 2027 August 27, 2021 28,571 28,571 $ 1.75 May 31, 2027 August 31, 2021 71,429 71,429 $ 1.75 May 31, 2027 September 1, 2021 228,572 228,572 $ 1.75 May 31, 2027 September 3, 2021 50,000 50,000 $ 1.75 May 31, 2027 September 9, 2021 88,571 88,571 $ 1.75 May 31, 2027 September 17, 2021 14,286 14,286 $ 1.75 May 31, 2027 September 20, 2021 422,856 422,856 $ 1.75 May 31, 2027 September 22, 2021 1,328,002 1,328,002 $ 1.75 May 31, 2027 September 23, 2021 500,000 500,000 $ 3.50 May 31, 2027 October 8, 2021 564,069 564,069 $ 1.75 May 31, 2027 October 22, 2021 281,964 281,964 $ 1.75 May 31, 2027 Total 12,383,550 12,383,550

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2021
Convertible Notes Payable
Convertible Notes Payable	Note 10 – Convertible Notes Payable Convertible notes payable consisted of the following at December 31, 2021 and 2020: Schedule of Convertible notes payable 2021 2020 Notes payable convertible into Clinigence common shares at $1.55 per share; bearing interest at a rate of 10%; net of debt discount of $3,904,221 and $0, respectively; maturing in July 2022 $ 3,904,221 $ — Included in the liabilities assumed in the AHA merger are convertible promissory notes to various individuals totaling 3,904,221 7,565,375 1.55 The debt discount of $ 7,565,375 3,904,221 1,820,000 1,173,834 At the time of issuance of these notes based on independent valuation, debt discounts were calculated and allocated based on the relative values of $ 2,658,960 4,906,415 3,703,134 1,086,095 Included in the liabilities assumed in the AHA merger are convertible promissory notes to an individual investor totaling $ 575,000 The note was entered into on August 25, 2020 and was convertible into AHA’s common stock contingent upon a merger transaction with a SPAC, which did not close. Under an Agreement with the investor signed on April 20, 2021, the Note was deemed to mature as of December 31, 2020 and accrued penalty interest was assessed through April 15, 2021 when the Note (including accrued interest) was to be converted into 625,313 shares of Clinigence common stock consisting of principal of $575,000 and penalty interest of $50,313, valued at $1.00 per share. On September 30, 2021, the Company entered into a promissory note settlement agreement whereby the noteholder converted the principal balance of $575,000 into 191,667 common shares valued at $3.00 per share, and the Company paid $51,750 of accrued interest to the noteholder

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes Payable	Note 11 – Notes Payable Notes payable consisted of the following at December 31, 2021 and 2020: Notes payable 2021 2020 Notes payable with maturities between six months and twelve months from the date of issuance with annual percentage interest rates between 24% and 31% $ — $ 1,765 SBA Paycheck Protection Program notes payable issued in April 2020 and February 2021 with maturity dates through August 2023 and interest rate of 1% 260,087 311,125 SBA Economic Injury Disaster Loan note payable issued in May 2020 with a maturity date of May 2051 and interest rate of 3.75% 150,000 150,000 Note payable with a maturity date of January 31, 2023 and interest rate of 12.9% 467,095 — Total notes payable 877,182 462,890 Current portion (727,182 ) (312,890 ) Total notes payable, net $ 150,000 $ 150,000 Beginning in April 2018, the Company entered into a series of short-term notes with interest rates ranging from 24 31 8,200 0 1,765 The Company’s long-term debt is comprised of promissory notes pursuant to the Paycheck Protection Program and Economic Injury Disaster Loan (see below), under Coronavirus Aid, Relief and Economic Security Act (“CARES ACT”) enacted on March 27, 2020 and revised under the provisions of the PayCheck Protection Flexibility Act of 2020 on June 5, 2020 and administered by the United States Small Business Administration (“SBA”). On May 22, 2020, the Company received loan proceeds of $ 150,000 U.S. Small Business Administration (“SBA”) COVID-19 Economic Injury Disaster Loan On April 21, 2020, the Company received a loan in the amount of $ 311,125 260,087 1 Under the terms of the loan, a portion or all of the loan is forgivable to the extent the loan proceeds are used to fund qualifying payroll, rent and utilities during a designated twenty-four week period. Payments are deferred until the SBA determines the amount to be forgiven. The Company has utilized the proceeds of the PPP loan in a manner which has enabled qualification as a forgivable loan. However, no assurance can be provided that all or any portion of the PPP loans will be forgiven. AHA’s PPP loans of $ 172,000 260,087 311,125 The Company assumed a note payable in the AHA merger transaction that AHA entered into with an individual investor on October 24, 2019. AHA issued a note with a principal amount of $ 700,000 50,000 1.55 12.9 April 29, 2021 Effective February 1, 2021, an Amended and Restated Note was entered into in which the principal amount increased to $ 840,000 12.9 840,000 467,095

Stock Transactions

Stock Transactions	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stock Transactions	Note 12 – Stock Transactions Common Stock Issued The Company sold 6,526,786 1.75 11,421,875 1,013,500 1,759,785 The Company sold 1,000,000 3.00 3,000,000 The Company sold 1,250 1.25 1,562 In connection with the convertible notes payable (see Note 10 above) various noteholders converted $ 2,395,000 1,365,501 During the year ended December 31, 2021, various shareholders exercised warrants in exchange for 106,578 153,424 On December 14, 2021, a shareholder exercised options in exchange for 89,421 2.00 178,842 In connection with the acquisition of Procare the Company issued 607,229 4.00 151,807 446,018 In connection with the acquisition of AHA the Company issued 14,218,241 2.06 In connection with the acquisition of AHP the Company issued 19,000,000 2.06 In connection with the AHA and AHP acquisitions, the Company issued 750,000 2.06 On January 28, 2021, the Company issued 182,567 153,606 .65 On January 28, 2021, the Company issued 46,154 30,000 The Company issued 225,820 361,312 23,276 33,750 The Company issued 228,346 290,000 On August 12, 2020, the Company sold 190,476 120,000 The Company issued 12,000 15,000

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 - Income Taxes Prior to March 1, 2019, the Company operated as a Limited Liability Company (“LLC”). Taxable income and losses of an LLC are passed through to its members and there is no entity level tax. Components of income tax expense (benefit) for the years ended December 31 consists of the following: Components of income tax expense 2021 2020 From Continuing Operations: Current: U.S. federal $ — $ — U.S. state and local — — Non-U.S. — — Total current income tax expense $ — $ — Deferred: U.S. federal $ (984,810 ) $ — U.S. state and local — — Non-U.S. — — Total deferred income tax expense (benefit) (984,810 ) — Change in valuation allowance — — Total deferred income tax expense (benefit) (984,810 ) — Income tax expense from discontinued operations — — Total income tax expense (benefit) $ (984,810 ) $ — The reconciliation between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense (benefit) is as follows: Schedule of Effective Income Tax Rate Reconciliation Years Ended December 31, 2021 2020 Statutory U.S. federal income tax rate 21.0 % 21.0 % State income taxes, net offederal income tax benefit (0.4 )% (0.3 )% Tax effect of expenses that are not deductible for income tax purposes: Accretion of debt (8.6 )% 0.0 % Impairment of goodwill (0.0 )% (12.8 )% Gain on sale of assets 0.0 % 7.4 % Other 0.9 % (1.3 )% Change in Valuation Allowance (19.6 )% (14.0 )% Effective tax rate (6.7 )% 0.0 % At December 31, the significant components of the deferred tax assets (liabilities) are summarized below: Schedule of deferred tax assets (liabilities) 2021 2020 Deferred Tax Assets: Net Operating Losses $ 3,162,746 $ 1,376,426 Charitable contributions 110 — Stock-based compensation 741,219 577,595 Total deferred tax assets 3,904,075 1,954,021 Deferred Tax Liabilities: Intangibles (1,747,250 ) — Total deferred tax liabilities (1,747,250 ) — Valuation Allowance (2,156,825 ) (1,954,021 ) Net deferred tax assets $ — $ — As of December 31, 2021, the Company had federal net operating loss carryforwards of approximately $ 13.3 AHP was incorporated in 2021 to facilitate the merger and will file separate federal and state tax returns on a standalone basis for the 2021 tax year. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax assets for every period because it is more likely than not that all of the deferred tax assets will not be realized. In accordance with ASC 740, a valuation allowance must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available positive and negative evidence, which includes, among other things, the Company’s most recent results of operations and expected future profitability. Based on the Company’s cumulative losses in recent years, a full valuation allowance against the Company’s deferred tax assets as of December 31, 2021 and 2020 has been established as Management believes that the Company will not more likely than not realize the benefit of those deferred tax assets. Therefore, no tax provision has been recorded for the years ended December 31, 2021 and 2020. The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10. The Company is subject to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or any states in connection with income taxes. The Company’s tax years generally remain open to examination for all federal and state income tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. The Company recognizes interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense. No interest or penalties have been recorded for the years ended December 31, 2021 and 2020, respectively. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOL’s incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company is currently evaluating the impact of the CARES Act, but at present does not expect that the NOL carryback provision of the CARES Act would result in a material cash benefit to us.

Concentrations and Credit Risk

Concentrations and Credit Risk	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Concentrations and Credit Risk	Note 14 – Concentrations and Credit Risk Sales and Accounts Receivable The Company had sales to two customers which accounted for approximately 13 10 10 The Company had sales to two customers which accounted for approximately 14 10 10 Cash Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $ 250,000

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 15 - Related Party Transactions Due to Related Parties Due to related parties with a balance of $ 128,176 30,000 128,176 30,000 January 28, 2021

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 16 – Commitments and Contingencies Employment Arrangements With Executive Officers The Company entered into 3-year employment agreements with Elisa Luqman and Dr. Lawrence Schimmel. Pursuant to the employment agreements with Ms. Luqman and Dr. Schimmel, each is entitled to receive a base annual salary of $ 150,000 180,000 250,000 250,000 150,000 250,000 Pursuant to the employment agreements with the named officers, upon termination, each such individual would be entitled to receive payment of all salary and benefits accrued up to the termination date of his or her employment in all employment termination events. Thereafter, Ms. Luqman would be entitled to receive twelve (12) months of base salary as a severance payment, Dr. Schimmel would be entitled to receive twenty-four (24) months of base salary as a severance payment, Dr. Hosseinion would be entitled to receive twenty four (24) months of base salary as a severance payment, Mr. Sternberg would be entitled to receive twenty four (24) months of base salary as a severance payment Mr. Bowen would be entitled to receive twelve (12) months of base salary as a severance payment, and Mr. Barnett would each be entitled to the balance of the remaining months under his employment agreement of base salary as a severance payment, upon termination of his or her employment by the Company without cause or by such individual for good reason. Effective April 1, 2017, in connection with the acquisition of HealthDatix Inc., the Company entered into employment agreements with Jerry Robinson, MaryJo Robinson, and Kathleen Shepherd each under a three-year term at a base salary of $ 75,000

Variable Interest Entities (VIE

Variable Interest Entities (VIEs)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities (VIEs)	Note 17 - Variable Interest Entities (VIEs) A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity’s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE. The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 3 to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment. The following table includes assets that can only be used to settle the liabilities of AHPIPA and the creditors of AHPIPA have no recourse to the Company. These assets and liabilities are included in the accompanying consolidated balance sheets. Schedule of consolidated balance sheets December 31, 2021 ASSETS Current Assets Cash and cash equivalents $ 3,215,844 Accounts receivable 369,539 Prepaid expenses and other assets 44,350 Total Current Assets 3,629,723 Other Assets Goodwill 31,733,526 Right of use asset, net 98,088 Intangible assets, net 6,555,306 Total Other Assets 38,386,920 Total Assets $ 42,016,643 Current Liabilities Accounts payable and accrued expenses $ 2,696,726 Lease liability - current 46,593 Total Current Liabilities 2,743,319 Long-term Liabilities Lease liability – long-term 55,906 Total Liabilities $ 2,799,225

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 18 – Subsequent Events The Company evaluated its December 31, 2021 consolidated financial statements for subsequent events through the date the consolidated financial statements were issued. Notes Payable Transactions On March 17, 2022, a noteholder converted $ 330,000 212,903 1.55 On February 22, 2022, Clinigence Health Inc.’s second PPP loan of $ 260,087 Planned Business Acquisition On March 16, 2022, the Company held a special meeting of stockholders in lieu of its annual meeting (the “Special Meeting”) to consider eight proposals related to the Company’s contemplated merger (the “Merger”) with Nutex Health Holdco LLC (“Nutex”) pursuant to the Agreement and Plan of Merger dated as of November 23, 2021 (the “Merger Agreement”) among the Company, Nutex, Nutex Acquisition LLC, Micro Hospital Holding LLC, Nutex Health LLC, and Tom Vo, as the Nutex Representative. Each of the Company’s proposals was approved by the requisite vote of the Company’s stockholders. At the close of business on January 27, 2022, the record date for the Special Meeting, there were 47,200,627 The proposal to approve the Merger and the other transactions contemplated by the Merger Agreement , including the issuance of shares of common stock of the Company to Nutex members as consideration in the Merger (Proposal No. 1), the proposal to approve the Amended and Restated Certificate of Incorporation of the Company (the “Charter”) to change the Company’s name, to increase the number of authorized shares of Common Stock of the Company and to remove authorized shares of preferred stock (Proposal No.2), the proposal to approve the Amended and Restated Bylaws (“Bylaws”) of the Company to change the Company’s name, change the voting threshold required to amend the Bylaws, and provide that the Court of Chancery in Delaware or state or federal courts located within Delaware be the exclusive forum over certain actions and claims (Proposal No. 3), the proposal to approve the Amended and Restated Nutex 2022 Equity Incentive Plan (Proposal No. 4), the proposal to elect seven directors to the Company’s board of directors (Proposal No. 5), the proposal to approve, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers pursuant to the golden parachute proposal (the “Golden Parachute Proposal”) (Proposal No. 6), the proposal to approve the auditor ratification (the “Auditor Ratification Proposal”) (Proposal No. 7) and the proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary (Proposal No. 8) each exceeded the requisite percentages for approval of such proposal. The stockholder approvals are subject to the completion of the Merger.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Clinigence Health, Inc., Accountable Healthcare America Inc., AHP Management Inc., and Procare Health, Inc. All intercompany accounts and transactions have been eliminated.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company’s significant estimates used in these financial statements include, but are not limited to, accounts receivable reserves, the valuation allowance related to the Company’s deferred tax assets, the recoverability and useful lives of long-lived assets, debt conversion features, stock-based compensation, certain assumptions related to the valuation of the reserved shares and the assets acquired and liabilities assumed related to the Company’s acquisitions. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Variable Interest Entities	Variable Interest Entities On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly-owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company’s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria: •The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and •The Company has a variable interest in the legal entity – i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity’s net assets. If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs. A legal entity is determined to be a VIE if it has any of the following three characteristics: 1. The entity does not have sufficient equity to finance its activities without additional subordinated financial support; 2. The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or 3. The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following: a. The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity’s economic performance, as evidenced by: i. Substantive participating rights in day-to-day management of the entity’s activities; or ii. Substantive kick-out rights over the party responsible for significant decisions; iii. The obligation to absorb the entity’s expected losses; or iv. The right to receive the entity’s expected residual returns. If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model. Variable interest model If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 17 – “Variable Interest Entities (VIEs)” to the consolidated financial statements for information on the Company’s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does not have any cash equivalents as of December 31, 2021 and 2020. The Company is exposed to credit risk in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured.
Accounts Receivable	Accounts Receivable The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment. As of December 31, 2021, no customers represented more than 10% of total accounts receivable.
Property and equipment and depreciation	Property and equipment and depreciation Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows: Schedule of estimated lives of respective assets Office equipment and fixtures 5 7 Computer hardware 5 Computer software 3 Development equipment 5
Amortization	Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows: Schedule of estimated lives of the respective assets Population Health Platform technology 11 Member relationships 15 Management contracts 15 years 15 Trademarks 6 10
Goodwill	Goodwill Goodwill represents the net identifiable assets acquired and the liabilities assumed of Procare, AHA and AHP and the fair market value of the common shares issued by the Company for the acquisition of Procare, AHA and AHP. In accordance with ASC Topic No. 350 “Intangibles – Goodwill and Other”), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be sufficient to recover the asset’s carrying amount, an impairment loss is charged to expense in the period identified. No impairment was recorded during the year ended December 31, 2021.
Long-Lived Assets	Long-Lived Assets The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.
Deferred Revenue	Deferred Revenue Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $ 173,919 76,687
Stock-Based Compensation	Stock-Based Compensation The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity,
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements .
Fair Value Measurements	Fair Value Measurements The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. The Company’s investment in AHA was valued at level 3 input. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.
Revenue Recognition	Revenue Recognition Revenue is generated by software licenses, training, and consulting. Software licenses are provided as SaaS-based subscriptions that grants access to proprietary online databases and data management solutions. Training and consulting are project based and billable to customers on a monthly-basis or task-basis. Revenue from training and consulting are generally recognized upon delivery of training or completion of the consulting project. The duration of training and consulting projects are typically a few weeks or months and last no longer than 12 months. SaaS-based subscriptions are generally marketed under multi-year agreements with annual, semi-annual, quarterly, or month-to-month renewals and revenue is recognized ratably over the renewal period with the unearned amounts received recorded as deferred revenue. For multiple-element arrangements accounted for in accordance with specific software accounting guidance, multiple deliverables are segregated into units of accounting which are delivered items that have value to a customer on a standalone basis. On January 1, 2019, the Company adopted the new revenue recognition standard Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit. Revenue from substantially all the Company’s contracts with customers continues to be recognized over time as performance obligations are satisfied. The Company provides its customers with software licensing, training, and consulting through SaaS-based subscriptions. This subscription revenue represents revenue earned under contracts in which the Company bills and collects the charges for licensing and related services. The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles: 1. Identifying the contract with a customer; 2. Identifying the performance obligations in the contract; 3. Determining the transaction price; 4. Allocating the transaction price to the performance obligations in the contract; and 5. Recognizing revenue when (or as) the Company satisfies its performance obligations. Revenues from subscriptions are deferred and recorded as deferred revenue when cash payments are received in advance of the satisfaction of the Company’s performance obligations and recognized over the period in which the performance obligations are satisfied. The Company completes its contractual performance obligations through providing its customers access to specified data through subscriptions for a service period, and training on consulting associated with the subscriptions. The Company primarily invoices its customers on a monthly basis and does not provide any refunds, rights of return, or warranties to its customers. AHA’s performance obligation is to manage ACO participants who provide healthcare services to CMS’s members for the purpose of generating shared savings. If achieved, the Company receives shared savings payments from CMS, which represents variable consideration. The shared savings payments are recognized using the most likely methodology. However, as the Company does not have sufficient insight from CMS into the financial performance of the shared risk pool because of unknown factors related to shifting patient count, risk adjustment factors and benchmark adjustments, among other factors, an estimate cannot be developed. Therefore, these amounts are considered to be fully constrained and only recorded in the months when such payments are known and/or received. The Company generally receives payment within ten months after the fiscal year-end. AHP negotiates fixed per-member, per-month (PMPM) rates (Capitation) with third-party insurers for a fixed period of time. The Independent Physicians Association (“IPA”) recognizes capitation payments received in advance from third-party insurers as revenue on a monthly basis without regard to the frequency, extent, or nature of the medical services actually furnished. Procare’s revenue is generated primarily through management fees that are received based on Gross Capitation Revenues of the IPA/Physician Groups. Revenue is paid monthly and is a flat fixed rate determined by the agreement. In addition to Management Fees, there is revenue generated through consultant services that are charged as a flat fixed rate and represent a small portion of the total revenue.
Advertising Costs	Advertising Costs The Company expenses advertising costs as incurred. Advertising costs of $ 24,449 41,418
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Fair Value Cash $ 81,316 Accounts receivable 284,847 Property and equipment 7,192 Management contracts 1,864,530 Trademarks 226,230 Accounts payable (95,236 ) Deferred tax liability - intangibles (439,060 ) Goodwill 945,115 Purchase price $ 2,874,934
Pro forma results of operation	Pro forma results of operation December 31, December 31, 2021 2020 Pro forma revenue $ 21,934,587 $ 20,776,209 Pro forma gross profit $ 4,647,452 $ 4,182,625 Pro forma loss from operations $ (15,215,466 ) $ (8,296,319 ) Pro forma net loss $ (12,346,906 ) $ (6,368,689 ) Pro forma net income (loss) per share $ (0.33 ) $ (1.29 ) Weighted average number of shares outstanding 37,325,057 4,942,268
A H A [Member]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Fair Value Cash $ 697,191 Other current assets 2,100 Investment in ACMG 7,134,000 PHP technology 2,183,000 Loan to Clinigence 85,000 Accounts payable (1,143,106 ) Due to related party (128,176 ) Notes payable (1,784,155 ) Deferred tax liability - intangibles (545,750 ) Goodwill 22,789,787 Purchase price $ 29,289,591
A H P [Member]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Fair Value Cash $ 3,105,877 Accounts receivable 269,315 Deposits and other assets 26,178 Member relationships 6,444,000 Trademarks 545,000 Accounts payable (2,683,896 ) Distribution payable (300,000 ) Deferred tax liability - intangibles (1,747,250 ) Goodwill 33,480,776 Purchase price $ 39,140,000 On September 30, 2021, the Company paid out an arbitration settlement on behalf of AHP. Pursuant to the merger agreement with AHP this triggered the release of 1,076,372 common shares that were subject to a holdback provision pending the outcome of the arbitration case (the “AHP Litigation Holdback Shares”) back to the Company. As a result of the release of the AHP Litigation Holdback shares to Clinigence Holdings, Inc. goodwill was decreased by $ 1,122,636

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2021
Discontinued Operations
Schedule of consolidated statements of operations	Schedule of consolidated statements of operations Sales $ 5,958 Cost of sales (6,795 ) General and administrative expenses (101,100 ) Depreciation and amortization (75 ) Interest expense (263 ) Loss from operations (102,275 ) Loss on disposal of HealthDatix (16,717 ) Loss from discontinued operations $ (118,992 )

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of estimated lives of respective assets	Schedule of estimated lives of respective assets Office equipment and fixtures 5 7 Computer hardware 5 Computer software 3 Development equipment 5
Schedule of estimated lives of the respective assets	Schedule of estimated lives of the respective assets Population Health Platform technology 11 Member relationships 15 Management contracts 15 years 15 Trademarks 6 10

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	Schedule of property, plant and equipment 2021 2020 Office equipment and fixtures $ 5,300 $ 5,300 Computer hardware 52,998 41,065 Computer software 16,121 16,121 Less: Accumulated depreciation (59,484 ) (50,095 ) Property, Plant and Equipment, Net $ 14,935 $ 12,391

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Schedule of intangible assets As of December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted Average Useful Life (in years) Amortized intangible assets: Member relationships $ 6,444,000 $ (358,000 ) $ 6,086,000 15 Management contracts 1,864,530 (31,076 ) 1,833,454 15 Trademarks 771,230 (81,350 ) 689,880 6 10 PHP technology 2,183,000 (206,742 ) 1,976,258 11 Total $ 11,262,760 $ (677,168 $ 10,585,592
Schedule of future amortization expenses	Schedule of future amortization expenses Aggregate Amortization Expense: For the year ended December 31, 2021 $ 677,168

Operating Lease (Tables)

Operating Lease (Tables)	12 Months Ended
	Dec. 31, 2021
Operating Lease
Schedule Operating lease ROU assets and operating lease liabilities	Schedule Operating lease ROU assets and operating lease liabilities December 31, 2021 Operating Lease: Operating lease right-of-use assets, net $ 98,008 Current portion of operating lease liabilities 46,593 Operating lease liabilities, net of current portion 55,906
Schedule summarizes maturities of operating lease liabilities	Schedule summarizes maturities of operating lease liabilities 2022 $ 51,800 2023 53,354 2024 4,457 Total lease payments 109,611 Less: Imputed interest 7,112 Present value of lease liabilities $ 102,499
Schedule minimum payments due under the non-cancelable lease	Schedule minimum payments due under the non-cancelable lease 2022 $ 51,800 2023 53,354 2024 4,457 Total minimum lease payments $ 109,611
Schedule of cash paid and related right-of-use operating lease recognized	Schedule of cash paid and related right-of-use operating lease recognized Year Ended December 31, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 50,292 Right-of-use lease assets obtained in the exchange for lease liabilities: Operating leases 27,472
Schedule of gain on lease termination	Schedule of gain on lease termination Current portion of operating lease liabilities at September 30, 2020 $ 54,564 Operating lease liabilities, net of current portion at September 30, 2020 182,059 Less: Operating lease right-of-use assets, net at September 30, 2020 211,449 Gain on lease termination $ 25,174

Earnings (Loss) Per Common Sh_2

Earnings (Loss) Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2021
Basic and fully diluted income (loss) per common share:
Computation of diluted net income (loss) per share	Computation of diluted net income (loss) per share Years Ended December 31, 2021 2020 Stock options 2,876,010 1,174,814 Stock warrants 12,383,550 557,873 Total shares excluded from calculation 15,259,560 1,732,687

Stock Based Compensation (Table

Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock option activities	Schedule of stock option activities Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Options outstanding at December 31, 2019 48,854 $ 5.11 8.05 Options granted 1,130,734 1.49 Options expired (400 ) 0.01 Options cancelled (4,374 ) 5.56 Options outstanding at December 31, 2020 1,174,814 1.61 8.11 Options granted 1,300,000 1.66 Options issued in merger 490,617 2.00 Options exercised (89,421 ) 2.00 Options outstanding at December 31, 2021 2,876,010 $ 1.69 6.90
Schedule of stock options outstanding	Schedule of stock options outstanding Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date August 5, 2019 40,480 40,480 $ 5.56 August 5, 2029 October 29, 2019 3,600 3,600 $ 0.0725 June 6, 2027 January 27, 2020 307,884 307,884 $ 1.50 January 27, 2030 January 27, 2020 225,000 225,000 $ 1.50 January 27, 2027 February 29, 2020 95,794 95,794 $ 1.25 February 28, 2030 May 11, 2020 380,000 380,000 $ 1.50 May 11, 2027 June 30, 2020 122,056 122,056 $ 1.45 June 30, 2030 January 28, 2021 1,000,000 1,000,000 $ 1.61 January 28, 2031 January 28, 2021 225,000 225,000 $ 1.61 January 28, 2028 February 25, 2021 201,196 201,196 $ 2.00 March 15, 2025 February 25, 2021 200,000 200,000 $ 2.00 February 25, 2031 August 16, 2021 75,000 75,000 $ 2.51 August 16, 2027 Total 2,876,010 2,876,010
Schedule of Warrants, Activity	Schedule of Warrants, Activity Warrants Warrants Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Warrants outstanding at December 31, 2019 1,065,251 $ 6.04 5.17 Warrants cancelled (507,378 ) — Warrants outstanding at December 31, 2020 557,873 6.77 3.79 Warrants granted 5,522,748 1.90 Warrants issued in merger 6,415,965 1.74 Warrants exercised (113,036 ) 1.45 Warrants outstanding at December 31, 2021 12,383,550 $ 2.04 4.64
Schedule of Outstanding Warrants	Schedule of Outstanding Warrants Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 21, 2019 96,433 96,433 $ 6.67 December 31, 2024 April 30, 2019 3,598 3,598 $ 6.67 December 31, 2024 May 13, 2019 14,393 14,393 $ 6.67 December 31, 2024 May 28, 2019 199,703 199,703 $ 6.67 December 31, 2024 June 5, 2019 7,197 7,197 $ 6.67 December 31, 2024 June 25, 2019 208,361 208,361 $ 6.67 December 31, 2024 September 6, 2019 25,188 25,188 $ 6.67 December 31, 2024 October 29, 2019 1,500 1,500 $ 25.00 February 5, 2023 October 29, 2019 1,500 1,500 $ 25.00 April 27, 2023 February 25, 2021 1,666,573 1,666,573 $ 1.55 October 31, 2025 February 25, 2021 500,000 500,000 $ 4.00 February 26, 2026 February 25, 2021 1,456,452 1,456,452 $ 1.55 February 1, 2027 February 25, 2021 2,694,190 2,694,190 $ 1.55 July 31, 2026 May 14, 2021 651,429 651,429 $ 1.75 May 30, 2027 May 28, 2021 228,571 228,571 $ 1.75 May 30, 2027 June 11, 2021 182,857 182,857 $ 1.75 May 30, 2027 June 22, 2021 137,143 137,143 $ 1.75 May 30, 2027 June 24, 2021 169,143 169,143 $ 1.75 May 30, 2027 June 28, 2021 45,714 45,714 $ 1.75 May 30, 2027 June 29, 2021 45,714 45,714 $ 1.75 May 30, 2027 July 6, 2021 28,571 28,571 $ 1.75 May 31, 2027 July 22, 2021 12,857 12,857 $ 1.75 May 31, 2027 July 29, 2021 57,142 57,142 $ 1.75 May 31, 2027 August 6, 2021 157,143 157,143 $ 1.75 May 31, 2027 August 10, 2021 14,286 14,286 $ 1.75 May 31, 2027 August 11, 2021 128,143 128,143 $ 1.75 May 31, 2027 August 12, 2021 42,857 42,857 $ 1.75 May 31, 2027 August 16, 2021 14,286 14,286 $ 1.75 May 31, 2027 August 17, 2021 14,286 14,286 $ 1.75 May 31, 2027 August 27, 2021 28,571 28,571 $ 1.75 May 31, 2027 August 31, 2021 71,429 71,429 $ 1.75 May 31, 2027 September 1, 2021 228,572 228,572 $ 1.75 May 31, 2027 September 3, 2021 50,000 50,000 $ 1.75 May 31, 2027 September 9, 2021 88,571 88,571 $ 1.75 May 31, 2027 September 17, 2021 14,286 14,286 $ 1.75 May 31, 2027 September 20, 2021 422,856 422,856 $ 1.75 May 31, 2027 September 22, 2021 1,328,002 1,328,002 $ 1.75 May 31, 2027 September 23, 2021 500,000 500,000 $ 3.50 May 31, 2027 October 8, 2021 564,069 564,069 $ 1.75 May 31, 2027 October 22, 2021 281,964 281,964 $ 1.75 May 31, 2027 Total 12,383,550 12,383,550

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Convertible Notes Payable
Schedule of Convertible notes payable	Schedule of Convertible notes payable 2021 2020 Notes payable convertible into Clinigence common shares at $1.55 per share; bearing interest at a rate of 10%; net of debt discount of $3,904,221 and $0, respectively; maturing in July 2022 $ 3,904,221 $ —

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes payable	Notes payable 2021 2020 Notes payable with maturities between six months and twelve months from the date of issuance with annual percentage interest rates between 24% and 31% $ — $ 1,765 SBA Paycheck Protection Program notes payable issued in April 2020 and February 2021 with maturity dates through August 2023 and interest rate of 1% 260,087 311,125 SBA Economic Injury Disaster Loan note payable issued in May 2020 with a maturity date of May 2051 and interest rate of 3.75% 150,000 150,000 Note payable with a maturity date of January 31, 2023 and interest rate of 12.9% 467,095 — Total notes payable 877,182 462,890 Current portion (727,182 ) (312,890 ) Total notes payable, net $ 150,000 $ 150,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Components of income tax expense	Components of income tax expense 2021 2020 From Continuing Operations: Current: U.S. federal $ — $ — U.S. state and local — — Non-U.S. — — Total current income tax expense $ — $ — Deferred: U.S. federal $ (984,810 ) $ — U.S. state and local — — Non-U.S. — — Total deferred income tax expense (benefit) (984,810 ) — Change in valuation allowance — — Total deferred income tax expense (benefit) (984,810 ) — Income tax expense from discontinued operations — — Total income tax expense (benefit) $ (984,810 ) $ —
Schedule of Effective Income Tax Rate Reconciliation	Schedule of Effective Income Tax Rate Reconciliation Years Ended December 31, 2021 2020 Statutory U.S. federal income tax rate 21.0 % 21.0 % State income taxes, net offederal income tax benefit (0.4 )% (0.3 )% Tax effect of expenses that are not deductible for income tax purposes: Accretion of debt (8.6 )% 0.0 % Impairment of goodwill (0.0 )% (12.8 )% Gain on sale of assets 0.0 % 7.4 % Other 0.9 % (1.3 )% Change in Valuation Allowance (19.6 )% (14.0 )% Effective tax rate (6.7 )% 0.0 %
Schedule of deferred tax assets (liabilities)	Schedule of deferred tax assets (liabilities) 2021 2020 Deferred Tax Assets: Net Operating Losses $ 3,162,746 $ 1,376,426 Charitable contributions 110 — Stock-based compensation 741,219 577,595 Total deferred tax assets 3,904,075 1,954,021 Deferred Tax Liabilities: Intangibles (1,747,250 ) — Total deferred tax liabilities (1,747,250 ) — Valuation Allowance (2,156,825 ) (1,954,021 ) Net deferred tax assets $ — $ —

Variable Interest Entities (V_2

Variable Interest Entities (VIEs) (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of consolidated balance sheets	Schedule of consolidated balance sheets December 31, 2021 ASSETS Current Assets Cash and cash equivalents $ 3,215,844 Accounts receivable 369,539 Prepaid expenses and other assets 44,350 Total Current Assets 3,629,723 Other Assets Goodwill 31,733,526 Right of use asset, net 98,088 Intangible assets, net 6,555,306 Total Other Assets 38,386,920 Total Assets $ 42,016,643 Current Liabilities Accounts payable and accrued expenses $ 2,696,726 Lease liability - current 46,593 Total Current Liabilities 2,743,319 Long-term Liabilities Lease liability – long-term 55,906 Total Liabilities $ 2,799,225

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details)	Dec. 31, 2021USD ($)
Cash	$ 81,316
Accounts receivable	284,847
Property and equipment	7,192
Management contracts	1,864,530
Trademarks	226,230
Accounts payable	(95,236)
Deferred tax liability - intangibles	(439,060)
Goodwill	945,115
Purchase price	2,874,934
A H A [Member]
Cash	697,191
Accounts payable	(1,143,106)
Deferred tax liability - intangibles	(545,750)
Goodwill	22,789,787
Purchase price	29,289,591
Other current assets	2,100
Investment in ACMG	7,134,000
PHP technology	2,183,000
Loan to Clinigence	85,000
Due to related party	128,176
Notes payable	1,784,155
A H P [Member]
Cash	3,105,877
Accounts receivable	269,315
Trademarks	545,000
Accounts payable	(2,683,896)
Deferred tax liability - intangibles	(1,747,250)
Goodwill	33,480,776
Purchase price	39,140,000
Deposits and other assets	26,178
Member relationships	6,444,000
Distribution payable	$ (300,000)

Organization and Basis of Pre_4

Organization and Basis of Presentation (Details-1) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Pro forma revenue	$ 21,934,587	$ 20,776,209
Pro forma gross profit	4,647,452	4,182,625
Pro forma loss from operations	(15,215,466)	(8,296,319)
Pro forma net loss	$ (12,346,906)	$ (6,368,689)
Pro forma net income (loss) per share	$ (0.33)	$ (1.29)
Weighted average number of shares outstanding	37,325,057	4,942,268

Organization and Basis of Pre_5

Organization and Basis of Presentation (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 24, 2021	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Preferred Stock description		Pursuant to the Procare Merger Agreement, at the Closing, the former Procare Stockholders were entitled to receive an aggregate of 759,036 Company Shares, 607,229 shares of which were valued at $4.00 per share with the remaining 151,807 shares valued at $446,018, are being held back and will be released subject to Procare achieving certain earnings milestones. Pursuant to the AHP Merger Agreement, at the Closing, the former AHP Stockholders were entitled to receive 19,000,000 Company Shares valued at $2.06 per share, inclusive of outstanding AHP options and warrants assumed by the Company, which constitutes 45% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options and warrants. For each share of AHP Shares, each former AHP Stockholder was entitled to receive 19,000,000 shares of Company Shares valued at $2.06 per share. Pursuant to the AHA Merger Agreement, at the Closing, the former AHA Stockholders were entitled to receive 14,034,472 Company Shares, inclusive of certain outstanding AHA options and warrants assumed by the Company, which constitutes 35% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options and warrants
Investment sold	$ 5,887,806	$ 5,887,806
Investment of cash	4,554,676	4,554,676	$ 0
Receivable	1,333,130	1,333,130
Increase in good will	$ 1,246,194
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest		1,122,636
Accumulated deficit		31,888,477	$ 18,218,962
Convertible debt		6,000,000
Cash and cash equivalents		$ 15,300,000

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Sales	$ 18,793,783	$ 1,585,952
Cost of sales	(14,647,045)	(909,780)
General and administrative expenses	(12,177,316)	(3,251,353)
Depreciation and amortization	(709,131)	(94,761)
Loss from operations	9,018,075	(1,373,320)
Loss from discontinued operations	0	$ (118,992)
Discontinued Operations [Member]
Sales	5,958
Cost of sales	(6,795)
General and administrative expenses	(101,100)
Depreciation and amortization	(75)
Interest expense	(263)
Loss from operations	(102,275)
Loss on disposal of HealthDatix	(16,717)
Loss from discontinued operations	$ (118,992)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2021
Office equipment and fixtures | Maximum [Member]
Property, Plant and Equipment [Line Items]
Office equipment useful life	5 years
Office equipment and fixtures | Minimum [Member]
Property, Plant and Equipment [Line Items]
Office equipment useful life	7 years
Computer hardware
Property, Plant and Equipment [Line Items]
Office equipment useful life	5 years
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Office equipment useful life	3 years
Development equipment
Property, Plant and Equipment [Line Items]
Office equipment useful life	5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2021
Population Health Platform Technology [Member]
Property, Plant and Equipment [Line Items]
Intangible assets useful life	11 years
Customer Relationships [Member]
Property, Plant and Equipment [Line Items]
Intangible assets useful life	15 years
Management Contract [Member]
Property, Plant and Equipment [Line Items]
Intangible assets useful life	15 years
Trademarks [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Intangible assets useful life	6 years
Trademarks [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Intangible assets useful life	10 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Deferred revenue	$ 173,919	$ 76,687
Advertising costs	$ 24,449	$ 41,418

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Office equipment and fixtures	$ 5,300	$ 5,300
Computer hardware	52,998	41,065
Computer software	16,121	16,121
Less: Accumulated depreciation	(59,484)	(50,095)
Property, Plant and Equipment, Net	$ 14,935	$ 12,391

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 4,648	$ 14,514

Intangible Assets (Details)

Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 11,262,760
Less: Accumulated amortization	(677,168)
Intangible Assets, Net	10,585,592
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	6,444,000
Less: Accumulated amortization	(358,000)
Intangible Assets, Net	$ 6,086,000
Intangible assets useful life	15 years
Management Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 1,864,530
Less: Accumulated amortization	(31,076)
Intangible Assets, Net	$ 1,833,454
Intangible assets useful life	15 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 771,230
Less: Accumulated amortization	(81,350)
Intangible Assets, Net	$ 689,880
Trademarks [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	6 years
Trademarks [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	10 years
Population Health Platform Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 2,183,000
Less: Accumulated amortization	(206,742)
Intangible Assets, Net	$ 1,976,258
Intangible assets useful life	11 years

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization Expense	$ 677,168	$ 222,032

Investment in ACMG (Details Nar

Investment in ACMG (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 24, 2021	Dec. 31, 2021	Dec. 31, 2020
Proceeds from investment	$ 5,887,806	$ 5,887,806
Subject to escrow		1,333,130
Settlement payment from ACMG		$ 522,000	$ 0
A C M G [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		29.00%
Ownership Interest		$ 7,134,000
A H A [Member]
Payment obligations		$ 15,000,000

Operating Lease (Details)

Operating Lease (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2020
Operating Lease:
Operating lease right-of-use assets, net	$ 98,008	$ 0	$ 211,449
Current portion of operating lease liabilities	46,593	0	54,564
Operating lease liabilities, net of current portion	$ 55,906	$ 0	$ 182,059

Operating Lease (Details 1)

Operating Lease (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Operating Lease
2022		$ 51,800
2023		53,354
2024		4,457
Total lease payments		109,611
Less: Imputed interest		7,112
Present value of lease liabilities		102,499
Current portion of operating lease liabilities	$ 54,564	46,593	$ 0
Operating lease liabilities, net of current portion	182,059	55,906	0
Less: Operating lease right-of-use assets	211,449	98,008	0
Gain on lease termination	$ 25,174	$ 0	$ 25,174

Operating Lease (Details 2)

Operating Lease (Details 2)	Dec. 31, 2021USD ($)
Operating Lease
2022	$ 51,800
2023	53,354
2024	4,457
Total minimum lease payments	$ 109,611

Operating Lease (Details 3)

Operating Lease (Details 3)	12 Months Ended
	Dec. 31, 2021USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 50,292
Right-of-use lease assets obtained in the exchange for lease liabilities:
Operating leases	$ 27,472

Operating Lease (Details Narrat

Operating Lease (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Operating Lease, Weighted Average Remaining Lease Term		2 years 1 month 6 days
Operating Lease, Weighted Average Discount Rate, Percent		6.75%
Gain on lease termination	$ 25,174	$ 0	$ 25,174
Letter of Credit		100,000
Loss on sale of assets		53,198
Continuing Operations [Member]
Rental expense		$ 100,009	$ 143,307

Earnings (Loss) Per Common Sh_3

Earnings (Loss) Per Common Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	15,259,560	1,732,687
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	2,876,010	1,174,814
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	12,383,550	557,873

Stock Based Compensation (Detai

Stock Based Compensation (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Options, Outstanding, Beginning Balance	1,174,814	48,854
Options, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 1.61	$ 5.11
Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 10 months 24 days	8 years 1 month 9 days	8 years 18 days
Options, Granted	1,300,000	1,130,734
Options, Granted, Weighted Average Exercise Price	$ 1.66	$ 1.49
Options, Expired		(400)
Options, Expired, Weighted Average Exercise Price		$ 0.01
Options, Cancelled		(4,374)
Options, Cancelled, Weighted Average Exercise Price		$ 5.56
Options, assumed in merger	490,617
Options, assumed in merger, Weighted Average Exercise Price	$ 2
Options exercised	(89,421)
Options, Exercised, Weighted Average Exercise Price	$ 2
Options, Outstanding, Ending Balance	2,876,010	1,174,814	48,854
Options, Outstanding, Ending Balance, Weighted Average Exercise Price	$ 1.69	$ 1.61	$ 5.11

Stock Based Compensation (Det_2

Stock Based Compensation (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Outstanding	2,876,010	1,174,814	48,854
Number Exercisable	2,876,010
Exercise price	$ 1.69	$ 1.61	$ 5.11
Options One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Aug. 5, 2019
Number of Outstanding	40,480
Number Exercisable	40,480
Exercise price	$ 5.56
Options outstanding Expiration Date	Aug. 5, 2029
Options Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Oct. 29, 2019
Number of Outstanding	3,600
Number Exercisable	3,600
Exercise price	$ 0.0725
Options outstanding Expiration Date	Jun. 6, 2027
Options Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jan. 27, 2020
Number of Outstanding	307,884
Number Exercisable	307,884
Exercise price	$ 1.50
Options outstanding Expiration Date	Jan. 27, 2030
Options Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jan. 27, 2020
Number of Outstanding	225,000
Number Exercisable	225,000
Exercise price	$ 1.50
Options outstanding Expiration Date	Jan. 27, 2027
Options Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 29, 2020
Number of Outstanding	95,794
Number Exercisable	95,794
Exercise price	$ 1.25
Options outstanding Expiration Date	Feb. 28, 2030
Options Six
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	May 11, 2020
Number of Outstanding	380,000
Number Exercisable	380,000
Exercise price	$ 1.50
Options outstanding Expiration Date	May 11, 2027
Options Seven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 30, 2020
Number of Outstanding	122,056
Number Exercisable	122,056
Exercise price	$ 1.45
Options outstanding Expiration Date	Jun. 30, 2030
Options 8 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jan. 28, 2021
Number of Outstanding	1,000,000
Number Exercisable	1,000,000
Exercise price	$ 1.61
Options outstanding Expiration Date	Jan. 28, 2031
Options 9 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jan. 28, 2021
Number of Outstanding	225,000
Number Exercisable	225,000
Exercise price	$ 1.61
Options outstanding Expiration Date	Jan. 28, 2028
Options 10 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	201,196
Number Exercisable	201,196
Exercise price	$ 2
Options outstanding Expiration Date	Mar. 15, 2025
Options 11 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	200,000
Number Exercisable	200,000
Exercise price	$ 2
Options outstanding Expiration Date	Feb. 25, 2031
Options 12 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Aug. 16, 2021
Number of Outstanding	75,000
Number Exercisable	75,000
Exercise price	$ 2.51
Options outstanding Expiration Date	Aug. 16, 2027

Stock Based Compensation (Det_3

Stock Based Compensation (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Warrants, Outstanding, Beginning Balance	557,873	1,065,251
Warrants, Outstanding, Beginning Balance	$ 6.77	$ 6.04
Warrants, Outstanding, Ending Balance	4 years 7 months 20 days	3 years 9 months 14 days	5 years 2 months 1 day
Warrants cancelled		(507,378)
Warrants Cancelled
Warrants Granted	5,522,748
Warrant Granted	$ 1.90
Warrants, assumed in merger	6,415,965
Warrants, assumed in merger, Warrants, assumed in merger	$ 1.74
Warrant Exercised	(113,036)
Warrants exercised	$ 1.45
Warrants, Outstanding, Ending Balance	12,383,550	557,873	1,065,251
Warrants, Outstanding, Ending Balance	$ 2.04	$ 6.77	$ 6.04

Stock Based Compensation (Det_4

Stock Based Compensation (Details 3)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Outstanding	12,383,550
Number Exercisable	12,383,550
Warrants One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Mar. 21, 2019
Number of Outstanding	96,433
Number Exercisable	96,433
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Apr. 30, 2019
Number of Outstanding	3,598
Number Exercisable	3,598
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	May 13, 2019
Number of Outstanding	14,393
Number Exercisable	14,393
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	May 28, 2019
Number of Outstanding	199,703
Number Exercisable	199,703
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 5, 2019
Number of Outstanding	7,197
Number Exercisable	7,197
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Six
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 25, 2019
Number of Outstanding	208,361
Number Exercisable	208,361
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Seven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Sep. 6, 2019
Number of Outstanding	25,188
Number Exercisable	25,188
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Eight
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Oct. 29, 2019
Number of Outstanding	1,500
Number Exercisable	1,500
Exercise price | $ / shares	$ 25
Expiration Date	February 5, 2023
Warrants Nine
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Oct. 29, 2019
Number of Outstanding	1,500
Number Exercisable	1,500
Exercise price | $ / shares	$ 25
Expiration Date	April 27, 2023
Warrants 10 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	1,666,573
Number Exercisable	1,666,573
Exercise price | $ / shares	$ 1.55
Expiration Date	October 31, 2025
Warrants 11 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	500,000
Number Exercisable	500,000
Exercise price | $ / shares	$ 4
Expiration Date	February 26, 2026
Warrants 12 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	1,456,452
Number Exercisable	1,456,452
Exercise price | $ / shares	$ 1.55
Expiration Date	February 1, 2027
Warrants 13 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	2,694,190
Number Exercisable	2,694,190
Exercise price | $ / shares	$ 1.55
Expiration Date	July 31, 2026
Warrants 14 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	May 14, 2021
Number of Outstanding	651,429
Number Exercisable	651,429
Exercise price | $ / shares	$ 1.75
Expiration Date	May 30, 2027
Warrants 15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	May 28, 2021
Number of Outstanding	228,571
Number Exercisable	228,571
Exercise price | $ / shares	$ 1.75
Expiration Date	May 30, 2027
Warrants 16 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 11, 2021
Number of Outstanding	182,857
Number Exercisable	182,857
Exercise price | $ / shares	$ 1.75
Expiration Date	May 30, 2027
Warrants 17 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 22, 2021
Number of Outstanding	137,143
Number Exercisable	137,143
Exercise price | $ / shares	$ 1.75
Expiration Date	May 30, 2027
Warrants 18 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 24, 2021
Number of Outstanding	169,143
Number Exercisable	169,143
Exercise price | $ / shares	$ 1.75
Expiration Date	May 30, 2027
Warrants 19 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 28, 2021
Number of Outstanding	45,714
Number Exercisable	45,714
Exercise price | $ / shares	$ 1.75
Expiration Date	May 30, 2027
Warrants 20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 29, 2021
Number of Outstanding	45,714
Number Exercisable	45,714
Exercise price | $ / shares	$ 1.75
Expiration Date	May 30, 2027
Warrants 21 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jul. 6, 2021
Number of Outstanding	28,571
Number Exercisable	28,571
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 22 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jul. 22, 2021
Number of Outstanding	12,857
Number Exercisable	12,857
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 23 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jul. 29, 2021
Number of Outstanding	57,142
Number Exercisable	57,142
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Aug. 6, 2021
Number of Outstanding	157,143
Number Exercisable	157,143
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 25 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Aug. 10, 2021
Number of Outstanding	14,286
Number Exercisable	14,286
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 26 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Aug. 11, 2021
Number of Outstanding	128,143
Number Exercisable	128,143
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 27 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Aug. 12, 2021
Number of Outstanding	42,857
Number Exercisable	42,857
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 28 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Aug. 16, 2021
Number of Outstanding	14,286
Number Exercisable	14,286
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 29 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Aug. 17, 2021
Number of Outstanding	14,286
Number Exercisable	14,286
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 30 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Aug. 27, 2021
Number of Outstanding	28,571
Number Exercisable	28,571
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 31 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Aug. 31, 2021
Number of Outstanding	71,429
Number Exercisable	71,429
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 32 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Sep. 1, 2021
Number of Outstanding	228,572
Number Exercisable	228,572
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 33 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Sep. 3, 2021
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 34 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Sep. 9, 2021
Number of Outstanding	88,571
Number Exercisable	88,571
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 35 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Sep. 17, 2021
Number of Outstanding	14,286
Number Exercisable	14,286
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 36 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Sep. 20, 2021
Number of Outstanding	422,856
Number Exercisable	422,856
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 37 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Sep. 22, 2021
Number of Outstanding	1,328,002
Number Exercisable	1,328,002
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 38 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Sep. 23, 2021
Number of Outstanding	500,000
Number Exercisable	500,000
Exercise price | $ / shares	$ 3.50
Expiration Date	May 31, 2027
Warrants 39 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Oct. 8, 2021
Number of Outstanding	564,069
Number Exercisable	564,069
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 40 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Oct. 22, 2021
Number of Outstanding	281,964
Number Exercisable	281,964
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027

Convertible Debt (Details)

Convertible Debt (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Convertible Notes Payables 1 [Member]
Short-term Debt [Line Items]
Total convertible notes payable	$ 3,904,221	$ 0

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 14, 2021	Oct. 02, 2021	Sep. 30, 2021	Sep. 29, 2021	Feb. 02, 2021
Debt Instrument, Face Amount						$ 840,000
Shares price	$ 1.75	$ 2	$ 4	$ 3	$ 1.25
Convertible Notes Payables [Member]
Debt Conversion, Converted Instrument, Amount	$ 2,658,960
Interest rate discount	4,906,415
Financing fees paid	1,086,095
Convertible Notes Payables [Member] | Warrant [Member]
Debt Conversion, Converted Instrument, Amount	3,703,134
A H A [Member]
Debt Discount (Premium)	7,565,375
A H A [Member] | Individuals [Member]
Debt Conversion, Converted Instrument, Amount	3,904,221
Debt Instrument, Face Amount	$ 7,565,375
Shares price	$ 1.55
Debt Discount (Premium)	$ 3,904,221
Accreted balance	$ 1,820,000
Common stock shares	1,173,834
A H A [Member] | Investor [Member]
Debt Conversion, Converted Instrument, Amount	$ 575,000
Merger transaction description	The note was entered into on August 25, 2020 and was convertible into AHA’s common stock contingent upon a merger transaction with a SPAC, which did not close. Under an Agreement with the investor signed on April 20, 2021, the Note was deemed to mature as of December 31, 2020 and accrued penalty interest was assessed through April 15, 2021 when the Note (including accrued interest) was to be converted into 625,313 shares of Clinigence common stock consisting of principal of $575,000 and penalty interest of $50,313, valued at $1.00 per share. On September 30, 2021, the Company entered into a promissory note settlement agreement whereby the noteholder converted the principal balance of $575,000 into 191,667 common shares valued at $3.00 per share, and the Company paid $51,750 of accrued interest to the noteholder

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Total notes payable	$ 877,182	$ 462,890
Current Portion	(727,182)	(312,890)
Total notes payable, net	150,000	150,000
Notes Payables 1 [Member]
Short-term Debt [Line Items]
Total notes payable	0	1,765
Notes Payables 2 [Member]
Short-term Debt [Line Items]
Total notes payable	260,087	311,125
Notes Payables 3 [Member]
Short-term Debt [Line Items]
Total notes payable	150,000	150,000
Notes Payables 4 [Member]
Short-term Debt [Line Items]
Total notes payable	$ 467,095	$ 0

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Feb. 02, 2021	Feb. 25, 2021	May 22, 2020	Apr. 21, 2020	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Interest rate	12.90%			1.00%
Proceeds from loan		$ 260,087		$ 311,125	$ 85,000	$ 0
Notes payable	$ 840,000				727,182	312,890
Face amount	$ 840,000
Short Term Notes [Member]
Short-term Debt [Line Items]
Periodic payments					8,200
Short-term notes					$ 0	1,765
Short Term Notes [Member] | Minimum [Member]
Short-term Debt [Line Items]
Interest rate					24.00%
Short Term Notes [Member] | Maximum [Member]
Short-term Debt [Line Items]
Interest rate					31.00%
S B A Loan [Member] | A H A [Member]
Short-term Debt [Line Items]
Proceeds from loan			$ 150,000
Related Party Loan Payable [Member]
Short-term Debt [Line Items]
Notes payable					$ 260,087	$ 311,125
Related Party Loan Payable [Member] | A H A [Member]
Short-term Debt [Line Items]
Notes payable					$ 172,000
Notes Payables [Member] | A H A [Member] | Investor [Member]
Short-term Debt [Line Items]
Interest rate					12.90%
Face amount					$ 700,000
Purchase cost					$ 50,000
Exercise price					$ 1.55
Maturity date					Apr. 29, 2021
Purchase aggregate					467,095

Stock Transactions (Details Nar

Stock Transactions (Details Narrative) - USD ($)	Dec. 14, 2021	Oct. 02, 2021	Sep. 11, 2020	Aug. 12, 2020	Jul. 12, 2020	Sep. 30, 2021	Sep. 29, 2021	Feb. 25, 2021	Jan. 28, 2021	Sep. 28, 2020	Jun. 30, 2020	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares sold						$ 1,000,000	$ 1,250					$ 1,000,000	$ 6,526,786
Share price	$ 2	$ 4				$ 3	$ 1.25					$ 3	$ 1.75
Investors for proceeds						$ 3,000,000	$ 1,562					$ 11,421,875
Placement agent													$ 1,013,500
Cash and issued warrants													1,759,785
Converted warrants													$ 2,395,000
Common stock shares													1,365,501
Number of shares exercised													89,421
Common Stock Issued for acquisition, shares		607,229
Number of shares acquired, value													$ 378,577
Shares issued for share based compensation, value													4,026,884	$ 2,571,689
Common stock shares issued, value													14,323,439	120,000
Proceeds from common stock sold													$ 14,323,439	$ 120,000
Former Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued									46,154
Payment to officer									$ 30,000
Officers And Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price per share									$ 0.65
Shares issued for share based compensation, shares									182,567
Directors And Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued for share based compensation, shares									153,606
Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued for share based compensation, shares											225,820
Shares issued for share based compensation, value											$ 361,312
Shares cancelled, shares										23,276
Shares cancelled, value										$ 33,750
Common stock shares issued, shares			12,000		228,346
Common stock shares issued, value			$ 15,000		$ 290,000
Directors and Investor
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of common stock, Shares				190,476
Proceeds from common stock sold				$ 120,000
Procare [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Issued for acquisition, shares		151,807
Number of shares acquired, value		$ 446,018
A H A [Member] | Shareholders [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Issued for acquisition, shares								14,218,241
Sale of Stock price per share								$ 2.06
Common Stock Issued for services								750,000
Share price per share								$ 2.06
A H P [Member] | Shareholders [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Issued for acquisition, shares								19,000,000
Sale of Stock price per share								$ 2.06
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares exercised													106,578
Number of shares exercised, value													$ 153,424
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares exercised	89,421
Number of shares exercised, value	$ 178,842

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current:
U.S. federal	$ 0	$ 0
U.S. state and local	0	0
Non-U.S.	0	0
Total current income tax expense	0	0
Deferred:
U.S. federal	(984,810)	0
U.S. state and local	0	0
Change in valuation allowance	0	0
Total deferred income tax expense (benefit)	(984,810)	0
Total deferred income tax expense (benefit)	(984,810)	0
Income tax expense from discontinued operations	0	0
Total income tax expense (benefit)	$ (984,810)	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory U.S. federal income tax rate	21.00%	21.00%
State income taxes, net offederal income tax benefit	(0.40%)	(0.30%)
Accretion of debt	(8.60%)	0.00%
Impairment of goodwill	(0.00%)	(12.80%)
Gain on sale of assets	0.00%	7.40%
Other	0.90%	(1.30%)
Change in Valuation Allowance	(19.60%)	(14.00%)
Effective tax rate	(6.70%)	0.00%

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets:
Net Operating Losses	$ 3,162,746	$ 1,376,426
Charitable contributions	110	0
Stock-based compensation	741,219	577,595
Total deferred tax assets	3,904,075	1,954,021
Deferred Tax Liabilities:
Intangibles	(1,747,250)	0
Total deferred tax liabilities	(1,747,250)	0
Valuation Allowance	(2,156,825)	(1,954,021)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	Jan. 31, 2021USD ($)
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 13,300,000

Concentrations and Credit Risk

Concentrations and Credit Risk (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Product Information [Line Items]
FDIC	$ 250,000
Sales [Member] | Customers [Member]
Product Information [Line Items]
Concentration percentage	13.00%	14.00%
Sales [Member] | Customers One [Member]
Product Information [Line Items]
Concentration percentage	10.00%	10.00%
Accounts Receivable [Member] | Customers [Member]
Product Information [Line Items]
Concentration percentage	10.00%	10.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Due to related parties	$ 128,176	$ 30,000
Proceeds from related party debt	0	$ 30,000
Shareholder And Former Officer [Member]
Related Party Transaction [Line Items]
Proceeds from related party debt	$ 30,000
Maturity date	Jan. 28, 2021
Shareholder And Former Officer [Member] | Assumed Liabilities, Net [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 128,176

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	12 Months Ended
	Dec. 31, 2021USD ($)
Defined Benefit Plan Disclosure [Line Items]
Base Salary	$ 75,000
Elisa Luqman [Member]
Defined Benefit Plan Disclosure [Line Items]
Base Salary	150,000
Lawrence Schimmel [Member]
Defined Benefit Plan Disclosure [Line Items]
Base Salary	180,000
Dr Hosseinion [Member]
Defined Benefit Plan Disclosure [Line Items]
Base Salary	250,000
Mr Sternberg [Member]
Defined Benefit Plan Disclosure [Line Items]
Base Salary	250,000
Mr Bowen [Member]
Defined Benefit Plan Disclosure [Line Items]
Base Salary	150,000
Mr Barnett [Member]
Defined Benefit Plan Disclosure [Line Items]
Base Salary	$ 250,000

Variable Interest Entities (V_3

Variable Interest Entities (VIEs) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2020
Current Assets
Cash and cash equivalents	$ 15,314,328	$ 26,931
Accounts receivable	647,325	18,283
Prepaid expenses and other assets	301,275	111,842
Total Current Assets	17,696,058	157,056
Goodwill	57,338,935	0
Right of use asset, net	98,008	0	$ 211,449
Total Assets	85,733,528	169,857
Current Liabilities
Accounts payable and accrued expenses	3,505,197	695,424
Lease liability - current	46,593	0	54,564
Total Current Liabilities	8,641,750	1,153,652
Long-term Liabilities
Lease liability – long-term	55,906	0	$ 182,059
Total Liabilities	10,594,906	$ 1,303,652
A H P I P A [Member]
Current Assets
Cash and cash equivalents	3,215,844
Accounts receivable	369,539
Prepaid expenses and other assets	44,350
Total Current Assets	3,629,723
Goodwill	31,733,526
Right of use asset, net	98,088
Intangible assets, net	6,555,306
Total Other Assets	38,386,920
Total Assets	42,016,643
Current Liabilities
Accounts payable and accrued expenses	2,696,726
Lease liability - current	46,593
Total Current Liabilities	2,743,319
Long-term Liabilities
Lease liability – long-term	55,906
Total Liabilities	$ 2,799,225

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended
	Mar. 17, 2022	Feb. 22, 2022	Jan. 27, 2022	Dec. 31, 2021	Dec. 14, 2021	Oct. 02, 2021	Sep. 30, 2021	Sep. 29, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Shares price				$ 1.75	$ 2	$ 4	$ 3	$ 1.25
Common shares outstanding				48,232,076					5,282,545
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt forgiven		$ 260,087
Common shares outstanding			47,200,627
Noteholder [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Converted debt	$ 330,000
Debt Conversion, Converted Instrument, Shares Issued	212,903
Shares price	$ 1.55